SWITCH ON: Analysing the Immunogenicity of Additional Booster Vaccinations in HCW

Summary

Eighty percent of the Dutch population has completed a primary COVID-19 vaccination regimen, and 60% of the population received a booster vaccination. Waning immunity, combined with the emergence of antigenically distinct SARS-CoV-2 variants, has led to the consideration of additional booster vaccinations in the Dutch population by autumn 2022. However, despite efforts of the Dutch policymakers, the public's willingness to repeatedly receive COVID-19 booster vaccinations is declining. This is mainly due to a reduced burden of disease by COVID-19, fewer hospitalizations, and fewer deaths. However, population immunity might be one of the major factors responsible for this reduced burden of disease, possibly emphasizing the need for booster vaccinations. In this proposal we will address an important question asked by policymakers: "Are booster vaccinations in autumn recommended for the healthy population?"

Timeline

Start

2022-08-20

Primary completion

2022-09-15

Completion

2023-08-30

Publications

• Tan NH, Lafeber M, Sablerolles RSG, Veerman Roders I, van de Hoef A, van Grafhorst K, Visser LG, Postma DF, Goorhuis A, Rietdijk WJR, van der Kuy PHM. Evaluation of a group-based online informed consent conversation (eConsent) in participants from a low-risk vaccination clinical trial. Trials. 2024 Aug 7;25(1):528. doi: 10.1186/s13063-024-08367-4.
• Tan NH, Geers D, Sablerolles RSG, Rietdijk WJR, Goorhuis A, Postma DF, Visser LG, Bogers S, van Dijk LLA, Gommers L, van Leeuwen LPM, Boerma A, Nijhof SH, van Dort KA, Koopmans MPG, Dalm VASH, Lafeber M, Kootstra NA, Huckriede ALW, van Baarle D, Zaeck LM, GeurtsvanKessel CH, de Vries RD, van der Kuy PHM; SWITCH ON Research Group. Immunogenicity of bivalent omicron (BA.1) booster vaccination after different priming regimens in health-care workers in the Netherlands (SWITCH ON): results from the direct boost group of an open-label, multicentre, randomised controlled trial. Lancet Infect Dis. 2023 Aug;23(8):901-913. doi: 10.1016/S1473-3099(23)00140-8. Epub 2023 Apr 21.
• Tan NH, Sablerolles RSG, Rietdijk WJR, Goorhuis A, Postma DF, Visser LG, Bogers S, Geers D, Zaeck LM, Koopmans MPG, Dalm VASH, Kootstra NA, Huckriede ALW, van Baarle D, Lafeber M, GeurtsvanKessel CH, de Vries RD, van der Kuy PM. Analyzing the immunogenicity of bivalent booster vaccinations in healthcare workers: The SWITCH ON trial protocol. Front Immunol. 2022 Nov 29;13:1067749. doi: 10.3389/fimmu.2022.1067749. eCollection 2022.

Drugs

Indications

No indication recorded.